Allspring Global Investments Holdings LLC Grows Position in Azenta, Inc. (NASDAQ:AZTA)

Allspring Global Investments Holdings LLC increased its holdings in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,317,385 shares of the company's stock after acquiring an additional 18,529 shares during the period. Allspring Global Investments Holdings LLC owned approximately 2.88% of Azenta worth $65,922,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of AZTA. Farther Finance Advisors LLC lifted its stake in shares of Azenta by 20.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company's stock valued at $74,000 after buying an additional 256 shares in the last quarter. QRG Capital Management Inc. raised its holdings in Azenta by 6.6% during the third quarter. QRG Capital Management Inc. now owns 6,156 shares of the company's stock valued at $298,000 after acquiring an additional 383 shares during the period. Ballentine Partners LLC lifted its position in shares of Azenta by 2.0% in the fourth quarter. Ballentine Partners LLC now owns 20,340 shares of the company's stock valued at $1,017,000 after acquiring an additional 404 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Azenta by 6.3% in the third quarter. Glenmede Trust Co. NA now owns 11,379 shares of the company's stock worth $551,000 after acquiring an additional 679 shares during the period. Finally, KBC Group NV boosted its stake in shares of Azenta by 48.5% in the fourth quarter. KBC Group NV now owns 2,137 shares of the company's stock worth $107,000 after acquiring an additional 698 shares during the period. Institutional investors own 99.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AZTA. Evercore ISI boosted their price target on Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a report on Thursday, February 6th. Stephens reissued an "overweight" rating and issued a $60.00 target price on shares of Azenta in a report on Thursday, January 2nd. Finally, Needham & Company LLC upped their target price on shares of Azenta from $55.00 to $59.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th.

Azenta Stock Up 0.7 %

Azenta stock traded up $0.31 during midday trading on Monday, reaching $45.41. 419,380 shares of the stock traded hands, compared to its average volume of 434,339. The stock has a market cap of $2.08 billion, a P/E ratio of -15.24 and a beta of 1.47. The stock's fifty day moving average is $50.53 and its 200-day moving average is $48.31. Azenta, Inc. has a 12 month low of $38.82 and a 12 month high of $67.77.

Azenta (NASDAQ:AZTA - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. On average, equities analysts predict that Azenta, Inc. will post 0.42 EPS for the current fiscal year.

Insider Buying and Selling at Azenta

In other Azenta news, CFO Herman Cueto sold 712 shares of the business's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total transaction of $28,529.84. Following the sale, the chief financial officer now directly owns 23,892 shares of the company's stock, valued at $957,352.44. The trade was a 2.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 1,423 shares of company stock worth $57,020 over the last 90 days. 10.62% of the stock is owned by insiders.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.